AP-III-a4(ENOblock) is primarily used in biomedical research as a small molecule inhibitor targeting the glycolytic enzyme enolase. It is known for its ability to modulate cellular metabolism by interfering with the Warburg effect, a metabolic pathway commonly upregulated in cancer cells. This makes it a valuable tool in oncology studies, particularly in exploring metabolic dependencies of tumor cells. It has been investigated for its anti-proliferative effects in various cancer models, including breast, lung, and liver cancers, where it suppresses cell growth and induces apoptosis. Additionally, AP-III-a4(ENOblock) shows potential in reducing inflammation and modulating immune responses, expanding its utility into immunological research. Due to its cell-permeable nature and specificity toward enolase, it is widely used in in vitro and in vivo experiments to dissect metabolic pathways and assess the therapeutic potential of metabolic inhibition. Its application supports the development of novel strategies for cancer treatment and metabolic disease research.